Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer

Over the last decade, the treatment of advanced non-small cell lung cancer (NSCLC) has undergone rapid changes with innovations in oncogene-directed therapy and immune checkpoint inhibitors. In patients with epidermal growth factor receptor (EGFR) gene mutant (EGFRm) NSCLC, newer-generation tyrosine...

Full description

Saved in:
Bibliographic Details
Main Authors: Nathaniel Wiest, Umair Majeed, Karan Seegobin, Yujie Zhao, Yanyan Lou, Rami Manochakian
Format: article
Language:EN
Published: Frontiers Media S.A. 2021
Subjects:
Non-small cell lung cancer
lung cancer
EGFR
tyrosine kinase inhibitor
immune-mediated adverse effects
immune checkpoint inhibitor (ICI)
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/8a8afaf9374b4c2f8f1ca6eb45e8a49c
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/8a8afaf9374b4c2f8f1ca6eb45e8a49c

Similar Items